Cubist Systematic Strategies LLC Purchases New Shares in Perspective Therapeutics, Inc. (NYSE:CATX)

Cubist Systematic Strategies LLC acquired a new stake in shares of Perspective Therapeutics, Inc. (NYSE:CATX - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 261,474 shares of the company's stock, valued at approximately $834,000. Cubist Systematic Strategies LLC owned approximately 0.39% of Perspective Therapeutics as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in the stock. BNP Paribas Financial Markets grew its holdings in shares of Perspective Therapeutics by 7.4% during the fourth quarter. BNP Paribas Financial Markets now owns 51,094 shares of the company's stock valued at $163,000 after buying an additional 3,529 shares during the last quarter. Rhumbline Advisers lifted its position in Perspective Therapeutics by 4.5% in the 4th quarter. Rhumbline Advisers now owns 94,992 shares of the company's stock valued at $303,000 after acquiring an additional 4,075 shares in the last quarter. Bank of New York Mellon Corp boosted its stake in Perspective Therapeutics by 3.4% during the 4th quarter. Bank of New York Mellon Corp now owns 143,469 shares of the company's stock valued at $458,000 after purchasing an additional 4,693 shares during the last quarter. JPMorgan Chase & Co. increased its holdings in shares of Perspective Therapeutics by 24.1% in the 3rd quarter. JPMorgan Chase & Co. now owns 24,912 shares of the company's stock worth $333,000 after purchasing an additional 4,844 shares in the last quarter. Finally, Trueblood Wealth Management LLC raised its stake in shares of Perspective Therapeutics by 37.0% in the fourth quarter. Trueblood Wealth Management LLC now owns 22,236 shares of the company's stock worth $71,000 after purchasing an additional 6,000 shares during the last quarter. Hedge funds and other institutional investors own 54.66% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the company. Cantor Fitzgerald raised Perspective Therapeutics to a "strong-buy" rating in a research report on Tuesday, March 4th. Royal Bank of Canada reduced their price target on shares of Perspective Therapeutics from $16.00 to $15.00 and set an "outperform" rating for the company in a research note on Thursday, March 27th. Lifesci Capital upgraded shares of Perspective Therapeutics to a "strong-buy" rating in a research report on Thursday, March 6th. Scotiabank initiated coverage on shares of Perspective Therapeutics in a research report on Friday, March 7th. They issued a "sector outperform" rating and a $15.00 target price for the company. Finally, Brookline Capital Management upgraded shares of Perspective Therapeutics to a "strong-buy" rating in a research note on Monday, March 10th. One analyst has rated the stock with a hold rating, seven have given a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat.com, Perspective Therapeutics presently has a consensus rating of "Buy" and a consensus target price of $12.50.

Insider Buying and Selling

In related news, CFO Juan Graham purchased 33,333 shares of the firm's stock in a transaction on Friday, March 28th. The shares were acquired at an average price of $2.25 per share, for a total transaction of $74,999.25. Following the purchase, the chief financial officer now directly owns 35,354 shares in the company, valued at $79,546.50. This trade represents a 1,649.33% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Johan M. Spoor acquired 22,026 shares of the business's stock in a transaction dated Friday, March 28th. The shares were purchased at an average price of $2.24 per share, with a total value of $49,338.24. Following the transaction, the chief executive officer now owns 59,383 shares of the company's stock, valued at approximately $133,017.92. This represents a 58.96% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last 90 days, insiders acquired 115,696 shares of company stock worth $256,344. 3.72% of the stock is owned by corporate insiders.

Perspective Therapeutics Trading Up 9.1%

Perspective Therapeutics stock traded up $0.22 during midday trading on Friday, hitting $2.63. The stock had a trading volume of 1,390,591 shares, compared to its average volume of 1,027,893. The firm's fifty day moving average is $2.24 and its two-hundred day moving average is $3.65. Perspective Therapeutics, Inc. has a 52-week low of $1.60 and a 52-week high of $16.90.

Perspective Therapeutics Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.